Back to today’s briefing

Story perspectives

First Patient Treated in Gene Editing Trial for GSD1a

7/11/2025

49 12

Summary

Story summary

UConn Health and Connecticut Children’s have launched a pioneering clinical trial, marking a significant milestone by treating the first patient with gene editing technology for glycogen storage disease type 1a (GSD1a). This cutting-edge therapy seeks to rectify genetic flaws in liver cells, igniting hope for affected patients and opening doors for future treatments of various genetic conditions.

1 of 1

Story summary

UConn Health and Connecticut Children’s have launched a pioneering clinical trial, marking a significant milestone by treating the first patient with gene editing technology for glycogen storage disease type 1a (GSD1a). This cutting-edge therapy seeks to rectify genetic flaws in liver cells, igniting hope for affected patients and opening doors for future treatments of various genetic conditions.